Hannah Clark, NP
Family · Holland, MINPI 1245614726
Payments from drug & device makers
Across 40 payments — averaging $112.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma Global Development$2K
- Astellas Pharma US Inc$841
- E.r. Squibb & Sons, L.L.C.$479
- Regeneron Healthcare Solutions, Inc.$245
- Gilead$244
- AstraZeneca$135
- plus $298 from 9 others
What the payments were for
- Consulting fees$2,25050%
- Food & beverage$2,05646%
- Education$1854%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma Global Development | 1 | $2,250 |
| Astellas Pharma US Inc | 13 | $841 |
| E.r. Squibb & Sons, L.L.C. | 4 | $479 |
| Regeneron Healthcare Solutions, Inc. | 2 | $245 |
| Gilead | 2 | $244 |
| AstraZeneca | 1 | $135 |
| AbbVie | 6 | $108 |
| Pfizer | 2 | $38 |
| Daiichi Sankyo Inc. | 2 | $32 |
| Bayer | 2 | $28 |
| Exeltis, USA Inc. | 1 | $23 |
| Stemline Therapeutics Inc. | 1 | $21 |
| Coopersurgical, Inc. | 1 | $19 |
| Ascend Therapeutics US, LLC | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,491 in reported general payments places this provider in the 90th percentile of 3,657 family providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 86 | $14,391 |
| Estradiol (Twice Weekly)Estradiol | 66 | $9,024 |
| ProgesteroneProgesterone, Micronized | 65 | $3,080 |
| DottiEstradiol | 17 | $2,692 |
| Clobetasol Propionate | 22 | $461 |
| Fluconazole | 20 | $131 |
| Triamcinolone Acetonide | 13 | $87 |
Paid to pharmacies, not to this prescriber.
Other family in Holland
- Christina Houck-SmithHolland$11K
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.